Is Astrana Health Inc (ASTH) overvalued? · P/E 34, rev $2.03B
Astrana Health Inc (ASTH) is a medical care facilities company listed on US.
This page asks whether Astrana Health Inc (ASTH) looks expensive on cached numbers — not a short thesis.
Latest reported ASTH revenue for 2024-12-31 was $2.03B. Net income was $49.9M. Revenue was up 46.7% from 2023-12-31 to 2024-12-31. ASTH currently screens at market cap $1.13B and trailing P/E 33.5.
ASTH currently screens at market cap $1.13B and trailing P/E 33.5. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ASTH 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ASTH stock page for the full model, not this heading.
Not investment advice.